ADC Therapeutics SA General And Administrative Expense
ADC Therapeutics SA (ADCT) reported General And Administrative Expense of $9.36 million for the 3-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:GeneralAndAdministrativeExpense · last filed 2023-11-07
- ADC Therapeutics SA general and administrative expense for the quarter ending 2023-09-30 was $9.36M, a 52.28% decline year-over-year.
- ADC Therapeutics SA general and administrative expense for the quarter ending 2023-06-30 was $11.35M, a 37.76% decline year-over-year.
- ADC Therapeutics SA general and administrative expense for the quarter ending 2023-03-31 was $15.14M, a 20.35% decline year-over-year.
- ADC Therapeutics SA general and administrative expense for the quarter ending 2022-12-31 was $15.14M, a 15.55% decline year-over-year.
| Period end | General And Administrative Expense 3 month | General And Administrative Expense 6 month | General And Administrative Expense 9 month | General And Administrative Expense 12 month |
|---|---|---|---|---|
| 2023-09-30 | $9.36M 6-K · filed 2023-11-07 | $20.71M derived: sum of 2 quarters · filed 2023-11-07 | $35.86M 6-K · filed 2023-11-07 | $50.99M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $11.35M 6-K · filed 2023-08-08 | $26.50M 6-K · filed 2023-08-08 | $41.63M derived: sum of 3 quarters · filed 2023-08-08 | $61.25M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $15.14M 6-K · filed 2023-05-09 | $30.28M derived: sum of 2 quarters · filed 2023-05-09 | $49.90M derived: sum of 3 quarters · filed 2023-11-07 | $68.14M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $15.14M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $34.76M derived: sum of 2 quarters · filed 2023-11-07 | $52.99M derived: sum of 3 quarters · filed 2023-11-07 | $72.01M 20-F · filed 2023-03-15 |
| 2022-09-30 | $19.62M 6-K · filed 2023-11-07 | $37.86M derived: sum of 2 quarters · filed 2023-11-07 | $56.87M 6-K · filed 2023-11-07 | $74.79M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $18.24M 6-K · filed 2023-08-08 | $37.25M 6-K · filed 2023-08-08 | $55.18M derived: sum of 3 quarters · filed 2023-08-08 | $71.76M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $19.01M 6-K · filed 2023-05-09 | $36.94M derived: sum of 2 quarters · filed 2023-05-09 | $53.52M derived: sum of 3 quarters · filed 2023-05-09 | $72.89M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $17.93M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $34.51M derived: sum of 2 quarters · filed 2023-03-15 | $53.88M derived: sum of 3 quarters · filed 2023-03-15 | $71.46M 20-F · filed 2023-03-15 |
| 2021-09-30 | $16.59M 6-K · filed 2022-11-08 | $35.95M derived: sum of 2 quarters · filed 2022-11-08 | $53.54M 6-K · filed 2022-11-08 | $73.63M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $19.37M 6-K · filed 2022-08-09 | $36.95M 6-K · filed 2022-08-09 | $57.05M derived: sum of 3 quarters · filed 2023-03-15 | $71.20M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $17.58M 6-K · filed 2022-05-09 | $37.68M derived: sum of 2 quarters · filed 2023-03-15 | $51.84M derived: sum of 3 quarters · filed 2023-03-15 | $66.83M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $20.10M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $34.25M derived: sum of 2 quarters · filed 2023-03-15 | $49.25M derived: sum of 3 quarters · filed 2023-03-15 | $55.13M 20-F · filed 2023-03-15 |
| 2020-09-30 | $14.16M 6-K · filed 2021-11-02 | $29.15M derived: sum of 2 quarters · filed 2021-11-02 | $35.03M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $14.99M 6-K · filed 2021-08-03 | $20.88M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | $5.88M 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $14.20M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $8.77M 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |